Sylentis Pipeline


Tivanisiran (SYL1001) is a small interfering RNA (siRNA) that is administered in solution as eye drops. It is currently in Phase 3 clinical research for the treatment of Dry Eye Disease.

This siRNA inhibits the synthesis of Transient Receptor Potential V1, also known as TRPV1 for Transient Receptor Potential Vanilloid-1.

TRPV1 is directly involved in the patho-physiology of Dry Eye Disease as it has a dual function on the ocular surface. It acts in the detection, transmission and regulation of sensation of pain in the eye, as well as in the mediation of innate inflammatory response, mechanisms whose regulation is key for the treatment and prevention of this disease.



  • Dry eye disease is caused by insufficient tear production, excessive tear evaporation or alterations in tear composition.
  • It is a very common chronic condition. It affects between 5 and 50% of the population.
  • Negative impact on patients’ visual health and quality of life.

Dry eye is a multi-factorial disease of the tear and ocular surface that causes discomfort, alterations in vision and even lesions in the outer layers of the eye.

Dry Eye Disease is chronic and has an associated inflammatory component, which can cause damage to the surface of the eye and even vision defects.